Sialyltransferase 7B (ST7B) is an enzyme belonging to the sialyltransferase family, which plays a critical role in the biosynthesis of sialic acid-containing glycoconjugates. Sialic acids are nine-carbon sugars that occupy the terminal positions of glycan chains on glycoproteins and glycolipids. These sialic acid residues are crucial for a myriad of biological processes, including cell-cell recognition, signaling, and immune responses. ST7B specifically catalyzes the transfer of sialic acid from the donor substrate cytidine monophosphate-sialic acid (CMP-sialic acid) to the terminal positions of oligosaccharides on glycoproteins and glycolipids. This enzymatic activity alters the surface properties of cells and can modulate cellular interactions and signaling pathways. The expression and activity of ST7B are thus essential for maintaining the sialoglycan diversity that underpins numerous physiological and pathological processes, including development, tissue homeostasis, and tumor metastasis.
The activation of ST7B, as with other glycosyltransferases, is intricately linked to the availability of its substrates and the cellular context. The concentration of CMP-sialic acid, the donor substrate, is a critical factor that can influence ST7B activity. Furthermore, the accessibility of acceptor substrates, such as nascent glycoproteins and glycolipids presenting the appropriate acceptor oligosaccharides, is also vital for ST7B function. Cellular localization plays a significant role in ST7B activation, as sialyltransferases are typically localized in the Golgi apparatus, where the sialylation process occurs. The regulation of ST7B activity can be influenced by the overall state of cellular glycosylation machinery, including the expression levels of other glycosyltransferases and the availability of transporters that facilitate the movement of substrates into the Golgi. Additionally, post-translational modifications of ST7B itself, such as phosphorylation, could modulate its activity, thereby affecting the enzyme's specificity and efficiency. Understanding the activation mechanisms of ST7B and its role in sialylation is crucial for comprehending how cells modulate their surface glycome in response to various physiological and pathological stimuli.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Tunicamycin | 11089-65-9 | sc-3506A sc-3506 | 5 mg 10 mg | $169.00 $299.00 | 66 | |
An inhibitor of N-linked glycosylation; can increase demand for other glycosylation processes, possibly escalating ST6GALNAC2 activity. | ||||||
Forskolin | 66575-29-9 | sc-3562 sc-3562A sc-3562B sc-3562C sc-3562D | 5 mg 50 mg 1 g 2 g 5 g | $76.00 $150.00 $725.00 $1385.00 $2050.00 | 73 | |
Elevates cyclic AMP (cAMP) levels and can influence glycosylation patterns, potentially affecting ST6GALNAC2 activity. | ||||||
2-Deoxy-D-glucose | 154-17-6 | sc-202010 sc-202010A | 1 g 5 g | $65.00 $210.00 | 26 | |
A glucose analog; its presence can impact glycosylation processes, potentially influencing ST6GALNAC2 function. | ||||||
MG-132 [Z-Leu- Leu-Leu-CHO] | 133407-82-6 | sc-201270 sc-201270A sc-201270B | 5 mg 25 mg 100 mg | $56.00 $260.00 $980.00 | 163 | |
A proteasome inhibitor; can impact protein degradation, possibly affecting proteins involved in ST6GALNAC2 regulation. | ||||||
Swainsonine | 72741-87-8 | sc-201362 sc-201362C sc-201362A sc-201362D sc-201362B | 1 mg 2 mg 5 mg 10 mg 25 mg | $135.00 $246.00 $619.00 $799.00 $1796.00 | 6 | |
An inhibitor of α-mannosidase, impacting glycosylation; its presence can indirectly influence ST6GALNAC2 activity. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
An inhibitor of MEK, a kinase involved in the MAPK pathway, which is linked to glycosylation; its action can influence ST6GALNAC2 activity. | ||||||
Thiamet G | 1009816-48-1 | sc-224307 sc-224307A | 1 mg 5 mg | $51.00 $94.00 | 1 | |
Inhibits O-GlcNAcase leading to increased O-GlcNAcylation; might indirectly impact ST6GALNAC2 by influencing overall glycosylation balance. | ||||||
N-(n-Butyl)deoxygalactonojirimycin | 141206-42-0 | sc-221974 | 5 mg | $343.00 | 4 | |
An inhibitor of glucosidase II; by impacting glycoprotein folding and maturation, can indirectly modulate ST6GALNAC2 activity. | ||||||